The role of radiotherapy in newly diagnosed primary CNS lymphoma: A descriptive review and a pragmatic approach to clinical practice

<p dir="ltr">Earlier, prior to the development of effective systemic therapy, monotherapy with whole-brain radiotherapy (WBRT) was widely used to treat <u>primary central nervous system lymphoma</u> (PCNSL). Recently, chemotherapy, especially with high dose methotrexate (...

Full description

Saved in:
Bibliographic Details
Main Author: Venkada Manickam Gurusamy (21792914) (author)
Other Authors: Saju Raveendran Divakar (21792917) (author), Suparna Halsnad Chandramouli (21792920) (author), Beena Kunheri (14779048) (author), Hissa Hussain Al-Abdulla (21792923) (author), Ghazia Shaikh (17346820) (author), Rajiv Chaudary Apsani (21792926) (author), Mohamed Riyaz Poolakundan (21792929) (author), Palmira Caparrotti (17346811) (author), Rabih Wafiq Hammoud (21792932) (author), Noora Al-Hammadi (17346808) (author)
Published: 2022
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<p dir="ltr">Earlier, prior to the development of effective systemic therapy, monotherapy with whole-brain radiotherapy (WBRT) was widely used to treat <u>primary central nervous system lymphoma</u> (PCNSL). Recently, chemotherapy, especially with high dose methotrexate (HDMTX), has largely replaced WBRT as upfront treatment, and the most accepted standard of care is induction with a combination drug therapy followed by consolidation therapy with either autologous stem-cell transplantation (ASCT) or radiation. Whilst WBRT is an effective component of treatment, it is occasionally associated with risk of permanent, irreversible <u>neurotoxicity</u> when doses of more than 30 Gy are used. Hence, there has been a strong focus on the optimization of radiotherapy (RT) which includes dose reduction in the consolidation phase. In this comprehensive review, we have summarized the progress on clinical results and evidence considering the role and use of radiation including combined treatment modalities, low-dose radiotherapy, and neurotoxicity. Finally, we present a practical approach to low-dose WBRT and boosting higher doses to the gross tumor that can be integrated into clinical practice.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical and Translational Radiation Oncology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.ctro.2022.12.002" target="_blank">https://dx.doi.org/10.1016/j.ctro.2022.12.002</a></p>